SCHEMBL5741222

SCHEMBL5741222

Cc1cccc2c1/C(=N/N)C(=O)N2

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.51
PDPK1 O15530 1/20 0.47
KDR P35968 1/20 0.47
RET P07949 4/20 0.46
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
ERBB2 P04626 2/20 0.42
CES1 P23141 1/20 0.41
ALDH1A1 P00352 1/20 0.40
MAPT P10636 1/20 0.40
HTT P42858 1/20 0.40
FLT3 P36888 1/20 0.40
PDGFRB P09619 2/20 0.39
PBRM1 Q86U86 1/20 0.38
IGF1R P08069 1/20 0.38
CA1 P00915 2/20 0.38
CA2 P00918 2/20 0.38
IDO1 P14902 1/20 0.38
LRRK2 Q5S007 1/20 0.38
CA9 Q16790 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7587270 0.84 POLB (0.50) POLBPDPK1KDRRETMEN1
SCHEMBL5740595 0.81 CES1 (0.61) CES1PBRM1IDO1
SCHEMBL9835981 0.81 CES1 (0.61) CES1PBRM1IDO1
SCHEMBL4163112 0.78 MAPT (0.60) POLBMEN1KMT2ACES1ALDH1A1
SCHEMBL2136384 0.77 CES1 (0.60) POLBPDPK1KDRRETERBB2
SCHEMBL18190769 0.76 MEN1 (0.43) POLBPDPK1KDRRETMEN1
SCHEMBL5739112 0.76 CES1 (0.50) POLBMEN1KMT2ACES1ALDH1A1
SCHEMBL5989290 0.73 LRRK2 (0.50) POLBKDRMEN1KMT2AALDH1A1
SCHEMBL11214209 0.73 CDC7 (0.43) POLBMEN1KMT2AALDH1A1MAPT
SCHEMBL11214211 0.73 CDC7 (0.43) POLBMEN1KMT2AALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1644362-A2 INDOLINONE HYDRAZIDES AS C-MET INHIBITORS Sugen, Inc. (US) 2006-04-12 EP disclosed
US-20060009493-A1 Indolinone hydrazides as c-Met inhibitors SUGEN, INC. 2006-01-12 US disclosed
WO-2005005378-A2 INDOLINONE HYDRAZIDES AS C-MET INHIBITORS SUGEN, INC. (US) 2005-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060009493-A1 Indolinone hydrazides as c-Met inhibitors MET, IGF1R, ROS1 POLB 4476/4885PDPK1 1952/4885KDR 637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.